What Is Survodutide?

Also known as: BI 456906, GLP-1/glucagon dual agonist

Survodutide (BI 456906) is a glucagon/GLP-1 dual receptor agonist developed by Boehringer Ingelheim with Zealand Pharma. The glucagon half raises energy expenditure and drives liver-fat clearance, while the GLP-1 half handles appetite and glucose.

Phase 2 data showed up to ~19% weight loss at 46 weeks and striking liver results — 83% of MASH patients improved without worsening fibrosis — which is why it is being pursued as a liver drug as much as a weight drug. Phase 3 SYNCHRONIZE trials are underway.

What is Survodutide studied for?

Side effects & safety

GI effects — nausea, vomiting, diarrhea — were the main cause of discontinuation in phase 2, especially with fast titration; glucagon activity can also raise heart rate.

Legal & approval status

Investigational; not approved anywhere. Research-market material is unregulated.

Typical dosing at a glance

Commonly reported protocols use 600 mcg–6 mg, 1x weekly, titrated up over ~20 weeks, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the Survodutide reconstitution calculator →

Related peptides

What is Semaglutide?What is Tirzepatide?What is Retatrutide?What is Cagrilintide?What is AOD-9604?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.